Thrombogenicity Comparison of Axial Ventricular Assist Devices by DTE Methodology: MicroMed HeartAssist 5 and Thoratec Heartmate II

Author(s):  
Wei-Che Chiu ◽  
Michalis Xenos ◽  
Yared Alemu ◽  
Gaurav Girdhar ◽  
Bryan Lynch ◽  
...  

Mechanical circulatory devices, such as ventricular assist devices (VADs), have become the life-saving alternative for the patients who suffered from severe heart failure (1). These devices were utilized as the bridge-transplant devices; however, due to the fast growing population of cardiovascular diseases and the eligible organ donations are very limited, these devices have been considered for the application of life-long implantation. The continuous-flow VADs offer better hemodynamic performance than the first generations pulsatile flow VADs, its compact design offers surgical advantage; however, due to the non-physiological blood flow past constricted geometrics where platelets are exposed to elevated wall shear stress (2), VADs are burdened with high incidence of thromboembolic events, mandating anticoagulation therapies for its recipients (3).

Author(s):  
Wei-Che Chiu ◽  
Yared Alemu ◽  
Bryan Lynch ◽  
Shmuel Einav ◽  
Marvin Slepian ◽  
...  

Congestive heart failure has reached epidemic proportions in the United States with more than 5.7 million patients suffering from it annually ( 1). Due to the limited availability of donor hearts, patients in their late stage heart failure who may require cardiac transplantation are dying while waiting for a matched heart. Mechanical circulatory support devices (MCS), such as ventricular assist devices (VAD), are utilized as a bridge to transplantation, and recently as destination therapy for extending the life of these patients. Continuous-flow VAD offer a surgical advantage over older generation pulsatile-flow VAD due to their compact design; however, due to the high RPM these VADs are operated with and the non-physiological blood flow patterns they generates, VADs are burdened with high incidence of thromboembolic events, and antiplatelet/anticoagulation regimens are mandated for the device recipients.


ASAIO Journal ◽  
2014 ◽  
Vol 60 (4) ◽  
pp. 369-371 ◽  
Author(s):  
Nicholas G. Kounis ◽  
George D. Soufras ◽  
Periklis Davlouros ◽  
Grigorios Tsigkas ◽  
George Hahalis

2012 ◽  
Vol 23 (1) ◽  
pp. 55-68 ◽  
Author(s):  
Timothy J. Myers

Morbidity and mortality in patients with cardiogenic shock remain high despite the recent advances in therapy. New temporary ventricular assist devices (VADs) that are rapidly applied to normalize cardiac output in patients with severe heart failure are being used more frequently. Bridge to decision describes the temporary use of a VAD to stabilize critically ill patients until complete diagnostic tests are performed and decisions about more definitive therapy are made. The CentriMag, Tandem-Heart, and Impella VADs offer versatility for use in many patients and in multiple hospital settings. These VADs provide continuous blood flow, altering the usual assessment of arterial blood pressure. Patients are usually immobilized during support to prevent dislodgement of cannulas. Anticoagulation therapy is commonly required, and bleeding is a frequent complication. Infection prevention measures must be used to avoid septic complications. In the past 10 years, clinical experience with these devices has expanded, but they remain underused.


2011 ◽  
Vol 92 (5) ◽  
pp. 1593-1600 ◽  
Author(s):  
Ranjit John ◽  
Forum Kamdar ◽  
Peter Eckman ◽  
Monica Colvin-Adams ◽  
Andrew Boyle ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document